Even though the clinical relevance on the aforementioned cardiovascular chance factor alterations by tirzepatide will probably be assessed within the prepared cardiovascular final result examine SURPASS-CVOT ( "variety":"clinical-trial","attrs": "textual content":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular met